CRP and metabolic syndrome: A growing body of epidemiological evidence suggests that the intake of iTFAs is associated with an increased risk of various disorders, such as cardiovascular diseases (CVDs), neurodegenerative diseases (NDs), metabolic syndrome, and systemic inflammation, as evidenced by elevated levels of inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6).3